Stifel Reiterates Repare Therapeutics (RPTX) at Buy, RP-3500 Safety Profile Raises Some Concerns, but Optimistic its Combination with PARPI's is Feasible
Tweet Send to a Friend
Stifel analyst Benjamin J. Burnett reiterated a Buy rating and {REMOVEPT} price target on Repare Therapeutics (NASDAQ: RPTX), following recently ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
